Steve joined Sofinnova as an Associate in 2017. In 2019, he was promoted to Senior Analyst. He focuses on public investments in global therapeutics companies. He has more than a decade of sell-side and buy-side experience following therapeutics companies.
Before joining Sofinnova, Steve covered therapeutics companies at Surveyor Capital, a global multi-strategy hedge fund associated with Citadel LLC. Prior to this, he was a senior manager of finance at Amgen, a global biotech company where he conducted Aranesp sales forecasts. Additionally, he worked as a sell-side biotech analyst/associate at Leerink Partners, UBS and Sanford C. Bernstein.
Steve received his Masters of Business and Science from Keck Graduate Institute and his B.S. from MIT.